Showing results (101-110 of 110) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.Intestinal Research|September 29, 2025
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Francesco Costa, et al.Expert Opinion on Biological Therapy|January 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.Advances in Therapy|May 9, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort StudyAntonio Tursi, Andrea Pasta, Walter Elisei, et al.Expert Opinion on Biological Therapy|February 27, 2023
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter studyGiammarco Mocci, Antonio Tursi, Giovanni Maconi, et al.Journal of Clinical Medicine|November 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.Journal of Clinical Medicine|December 17, 2024
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.American Journal of Therapeutics|July 23, 2026
Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life StudyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.Pageof 11